Marks & Clerk‘s offering has noteworthy abilities handling complex patent matters for clients spanning sectors including electronics and software, medtech, pharma and life sciences, amongst many others. Its workload incorporates advising on multi-jurisdictional patent portfolio management, freedom to operate, patent filings and related strategy. Additionally, the team is experienced acting in litigious contexts before the UPC and various UK courts, as well as in EPO opposition matters. Names to note include Will Nieuwenhuys who manages global portfolios, prosecutes patents in UK courts and before the EPO and handles patent drafting matters, and Thomas Prock who leads the team’s UPC group and harnesses expertise across various contentious matters. The practice is overseen by Simon Mounteney and Robin Oxley. Sheila Wallace retired in April 2024.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'We have worked with Marks & Clerk for many years. Their practice stands out as encompassing both high quality technical ability and excellent, tailored advice and service.'
- 'They know their stuff and are trustworthy.'
- 'Every member of the Marks & Clerk patent team is both personable and has exceptional intellect to quickly understand all types of technology and apply the necessary expertise to advocate for a successful outcome.'
- 'The team is very responsive and produces high quality results.'
- 'All the associates and partners that we have worked with at Marks and Clerk are outstanding technically and legally.'
- 'Daniel Sizer is a pleasure to work with. He is eager, detail-oriented and has a commercially pragmatic approach to the client's tasks at hand.'
Key clients
- AbbVie
- AB-InBev
- Advanced Medical Solutions
- ams-OSRAM
- Bridgestone
- Chugai Pharmaceuticals
- Daiichi Sankyo
- Genentech
- Genuit Group
- Gilead Sciences
- Lenovo
- Manitou
Work highlights
Advising Daiichi Sankyo on patent and SPC portfolios relating to antibody-drug conjugates (ADCs) for treatment of cancers, including important commercial products.
Advising Meril Life Sciences on its legal battles across Europe with well-known medical device company Edwards Lifesciences around replacement heart valve technology.
Advising Gilead Sciences on European patent portfolios relating to a number of areas including liver disease (particularly HCV, HBV and NASH) and cardiovascular disease.
Practice head
Simon Mounteney; Robin Oxley
Other key lawyers
Will Nieuwenhuys; Thomas Prock; Jonathan Stafford; Daniel Sizer; Matthew Jefferies; David Lang; Sophie Topham; Pam Bryer; Peter Roberts